SPY411.49+2.97 0.73%
DIA337.86+2.73 0.81%
IXIC13,900.19+70.88 0.51%

BRIEF-Fibrogen Initiates Lelantos-2 – Second Phase 3 Clinical Study Of Pamrevlumab For The Treatment Of Duchenne Muscular Dystrophy

· 03/16/2021 07:22
BRIEF-Fibrogen Initiates Lelantos-2 – Second Phase 3 Clinical Study Of Pamrevlumab For The Treatment Of Duchenne Muscular Dystrophy

- FibroGen Inc FGEN.O:

  • FIBROGEN INITIATES LELANTOS-2 – SECOND PHASE 3 CLINICAL STUDY OF PAMREVLUMAB FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Source text for Eikon: ID:nGNX7sHQG7

Further company coverage: FGEN.O


((Reuters.Briefs@thomsonreuters.com;))